



Theratechnologies To Develop Tesamorelin For The Treatment Of Nash In The General Population

September 10, 2020

Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021

Clinical study to include HIV cohort

Montreal, Canada – September 10, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in the general population.